Neurogene Adjusts NGN-401 Trial After Adverse Event

Neurogene ( (NGNE) ) has provided an update.

Neurogene Inc. updates its clinical trial for NGN-401 gene therapy targeting Rett syndrome after a serious adverse event in a high-dose participant led to critical conditions. While the FDA allows continuation at a lower dose, further high-dose enrollments are paused. Safety remains a priority as the trial progresses with no other adverse events reported at lower doses, showcasing potential for future treatments of neurological diseases.

For a thorough assessment of NGNE stock, go to TipRanks’ Stock Analysis page.